1. Zur Hausen H. Papillomaviruses in the causation of human cancers — a brief historical account. Virology. 2009;384:260-5.
  2. Alemany L, Pérez C, Tous S, Llombart-Bosch A, Lloveras B, Lerma E, et al. Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention. Gynecol Oncol. 2012;124:512-7.
  3. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12-23.
  4. World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec. 2017;92:241-68.
  5. Chow E, Danielewski J, Fehler G, Tabrizi S, Law M, Bradshaw CS,et al. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Lancet Infect Dis. 2015;15:1314-23.
  6. Smith L, Strumpf E, Kaufman J, Lofters A, Schwandt M, Lévesque L. The early benefits of human papillomavirus vaccination in cervical displasia and anogenital warts. Pediatrics. 2015;133:e1131.
  7. Mesher D, Panwar K, Thomas S, Beddows S, Soldan K. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. BMJ Open. 2016;6:e009915.
  8. Baldur-Felskov B, Dehlendorff C, Junge J, Munk C, Kjaer S. Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control. 2014;25:915.
  9. Herweijer E, Sundström K, Ploner A, Uhnoo I, Sparén P, Arnheim-Dahlström L. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: a population-based study. Int J Cancer. 2016;138:2868-74.
  10. Markowitz L, Liu G, Hariri S, Steinau M, Dunne E, Unger E. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137:e20151968.
  11. Kjaer S, Nygard M, Dillner J, Brooke Marshall J, Radley D, Li M, et al. A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 Nordic countries. Clin Infect Dis. 2018;66:339-45.
  12. Lehtinen M, Lagheden C, Loustarinen T, Eriksson T, Apter D, Harjula K, et al. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials. BMJ Open. 2017;7:e015867.
  13. World Health Organization. Meeting of the Global Advisory Committee on Vaccine Safety, 7-8 June 2017. Wkly Epidemiol Rec. 2017;92:393-403.
  14. Garland S, Kjaer S, Muñoz N, Block S, Brown D, DiNubile M, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63:519-27.
  15. Ministerio de Sanidad, Servicios Sociales e Igualdad. Ponencia de Programa y Registro de Vacunación. Revisión del programa de vacunación frente al virus del papiloma humano. Informes, Estudios e Investigación; 2013.
  16. Mesher D, Soldan K, Lehtinen M, Beddows S, Brisson M, Brotherton JM, et al. Population-level effects of human papillomavirus vaccination programs on infections with non vaccine types. Emerg Infect Dis. 2016;22:1732-40.
  17. Centers for Disease Control and Prevention. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 – United States. MMWR Morb Mortal Wkly Rep. 2013;62:591-5.
  18. Medicines and Healthcare Products Regulatory Agency. United Kingdom. Cervarix HPV vaccine: update on UK safety experience at end of 4 years use in the HPV routine immunisation programme. December 2012. Disponible en:
  19. Australian Government. Enhanced school-based surveillance of acute adverse events following immunization with human papillomavirus vaccine in males and females, 2013. May 2015. Disponible en:
  20. World Health Organization. Global Advisory Committee on Vaccine Safety, 11-12 December 2013. Wkly Epidemiol Rec. 2014; 89:53-6 0.
  21. Stillo M, Carrillo Santiesteve P, Lopalco P. Safety of human papillomavirus vaccines: a review. Exp Opin Drug Safety. 2015;14:697-712.
  22. European Medicines Agency. Review concludes evidence does not support that vaccines cause CRPS or POTS. November 2015. Disponible en:
  23. World Health Organization. Information sheet. Observed rate of vaccine reactions. Human Papilloma Virus Vaccine. June 2012.

Subir al menú